Business Context and Reporting Period
This Form 8-K filing by Accuray Incorporated reports corporate governance changes effective February 5, 2008. The report was filed on February 8, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board appointments and does not contain financial performance data.
Material Changes
The Board of Directors increased the authorized number of directors from six to eight. Two new independent directors were appointed:
- John P. Wareham: Appointed as a Class II director. He is currently Chairman of Steris Corporation and formerly served as CEO of Beckman Coulter, Inc. He will chair a newly established Corporate Strategy Committee.
- Elizabeth Davila: Appointed as a Class III director. She is the former Chairman and CEO of VISX, Incorporated (acquired by Advanced Medical Optics in 2005).
These appointments result in a majority of the Board being independent under Nasdaq Global Market rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation, the new directors will receive standard non-employee director compensation as described in the 2007 proxy statement, with Mr. Wareham receiving additional compensation for chairing the Corporate Strategy Committee. The company confirmed no undisclosed arrangements or material financial interests involving the new directors.
Investor Verification Checklist
- Verify the independence status of the new directors under Nasdaq rules.
- Review the 2007 proxy statement for details on director compensation structures.
- Confirm the composition of the new Corporate Strategy Committee.
- Check for any subsequent filings regarding the election of these directors at the 2008 and 2009 annual meetings.